Illumina’s COVIDSeq Test Granted Emergency Use Authorization. See Also: CRISPR Therapeutics and Vertex Encouraging News

Illumina Diagnostic Test COVIDSeq to Detect SARS-CoV-2
Illumina (ILMN) was issued an Emergency Use Authorization (EUA) from the FDA for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The authorization was granted for the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.